High Virologic Suppression Rates Observed with B/F/TAF in HIV/AIDS Patients in Argentina

Strategic Insights -

A study published in the journal Medicina-buenos Aires has presented real-world data on the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treating HIV/AIDS patients in Argentina. The research, conducted by a team of Argentine scientists, aimed to describe the safety, persistence, and virologic suppression (VS) rates in people living with HIV (PLWH) who started B/F/TAF from October 2019 to January 2024.

Key Takeaways:

  • The BIC-CD4 study included 3527 patients starting B/F/TAF, with 250 (7%) having a CD4 count of 99% or higher in both treatment-naive (TN) and experienced (TE) groups.
  • Median CD4 counts increased in both TEU and TENU groups, indicating improved immune system function.
  • No adverse events were reported in the study, suggesting the safety of B/F/TAF in PLWH.
  • The study demonstrated excellent persistence, safety, and adequate VS rates in PLWH with advanced HIV disease, supporting the use of B/F/TAF in this population.

Statistics:

  • 3527 patients started B/F/TAF during the study period.
  • 250 (7%) of patients had a CD4 count of 99% or higher.
  • Median CD4 counts increased in both TEU and TENU groups.
  • No adverse events were reported during the study.

Sources:

  • Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease. Medicina-buenos Aires, 2025;85(5):991-998.
  • Studies from Diego Cecchini et al in the Area of HIV/AIDS Described (Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease). AIDS Weekly. November 3, 2025; p 126.